Inclusion criteria include:  Age 3 months through 17 years Weight > 3 kg Documented HIV infection by DNA polymerase chain reaction (PCR) or plasma RNA-PCR if <18 months and by HIV-ELISA if 18 months and confirmed with a DNA PCR or RNA-PCR from an independent sample Undetectable HIV-1 viral load  Exclusion criteria  Confirmed or suspected TB disease (evidenced by symptoms and/or clinical exam findings and/or chest radiographic findings suggestive of TB, positive mycobacterial culture or molecular TB testing, or currently on TB treatment for active TB disease) Likely to move from the study area during the study period Known exposure to TB cases with known or suspected resistance to isoniazid or rifampicin in the source case TB treatment within the past year Prior completion of a TPT course without re-exposure to persons with infectious TB since TPT completion Receipt of once-daily INH for >30 days that was given for at least 14 consecutive days in the 30 days prior to enrolment. Sensitivity or intolerance to dolutegravir, isoniazid, or rifamycins Suspected acute hepatitis or known chronic or unstable liver disease^; HBsAg positivity or anti-hepatitis A virus (HAV) Immunoglobulin M (IgM) antibody; any infant born to a Hepatitis C positive mother in whom in utero infection in the infant is unknown or under evaluation alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN) Total bilirubin > 2 .5 times the ULN Absolute neutrophil count (ANC) ≤ 750 cells/mm3 Estimated creatinine clearance < 60 ml/min (Bedside Schwartz formula)* Pregnancy or breastfeeding (infant of a breastfeeding mother is allowed) Women of childbearing potential who are unable or unwilling to use two forms of contraception** Weight for age Z score below 2 or severe clinical malnutrition On prohibited medications e.g. dofetilide (see Appendix 1) Known porphyria